Physician profile
Bina Taibi
NPI 1306012588
$8,360.61
in general payments reported to CMS, 2019-2025
41 companies · $1,961 in 2025
The $1,961 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $488 · 2021: $980 · 2022: $1,163 · 2023: $1,590 · 2024: $1,875 · 2025: $1,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,408 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,407.65 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,729.65 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,006.48 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $735.26 | 2020-2025 | Farxiga, Airsupra, Tezspire |
| Dexcom, INC. | $492.80 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Lilly USA, LLC | $474.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $385.22 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $360.07 | 2019-2022 | |
| Astellas Pharma US INC | $335.63 | 2019-2025 | Veozah |
| Amgen INC. | $250.08 | 2024-2025 | Repatha, Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $230.33 | 2021-2022 | |
| Exact Sciences Corporation | $225.74 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $211.87 | 2024-2025 | Freestyle Libre 3 |
| Abbvie INC. | $198.66 | 2021-2024 | Qulipta, Vraylar |
| Merck Sharp & Dohme LLC | $193.13 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Horizon Therapeutics Plc | $164.00 | 2022-2023 | Krystexxa |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bina Taibi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.